Document Detail


Amyloid imaging in mild cognitive impairment subtypes.
MedLine Citation:
PMID:  19475670     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: We utilized the amyloid imaging ligand Pittsburgh Compound B (PiB) to determine the presence of Alzheimer's disease (AD) pathology in different mild cognitive impairment (MCI) subtypes and to relate increased PiB binding to other markers of early AD and longitudinal outcome.
METHODS: Twenty-six patients with MCI (13 single-domain amnestic-MCI [a-MCI], 6 multidomain a-MCI, and 7 nonamnestic MCI) underwent PiB imaging. Twenty-three had clinical follow-up (21.2 +/- 16.0 [standard deviation] months) subsequent to their PiB scan.
RESULTS: Using cutoffs established from a control cohort, we found that 14 (54%) patients had increased levels of PiB retention and were considered "amyloid-positive." All subtypes were associated with a significant proportion of amyloid-positive patients (6/13 single-domain a-MCI, 5/6 multidomain a-MCI, 3/7 nonamnestic MCI). There were no obvious differences in the distribution of PiB retention in the nonamnestic MCI group. Predictors of conversion to clinical AD in a-MCI, including poorer episodic memory, and medial temporal atrophy, were found in the amyloid-positive relative to amyloid-negative a-MCI patients. Longitudinal follow-up demonstrated 5 of 13 amyloid-positive patients, but 0 of 10 amyloid-negative patients, converted to clinical AD. Further, 3 of 10 amyloid-negative patients "reverted to normal."
INTERPRETATION: These data support the notion that amyloid-positive patients are likely to have early AD, and that the use of amyloid imaging may have an important role in determining which patients are likely to benefit from disease-specific therapies. In addition, our data are consistent with longitudinal studies that suggest a significant percentage of all MCI subtypes will develop AD.
Authors:
David A Wolk; Julie C Price; Judy A Saxton; Beth E Snitz; Jeffrey A James; Oscar L Lopez; Howard J Aizenstein; Ann D Cohen; Lisa A Weissfeld; Chester A Mathis; William E Klunk; Steven T De-Kosky; Steven T DeKoskym
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.    
Journal Detail:
Title:  Annals of neurology     Volume:  65     ISSN:  1531-8249     ISO Abbreviation:  Ann. Neurol.     Publication Date:  2009 May 
Date Detail:
Created Date:  2009-06-03     Completed Date:  2009-06-26     Revised Date:  2014-09-09    
Medline Journal Info:
Nlm Unique ID:  7707449     Medline TA:  Ann Neurol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  557-68     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Amyloid / metabolism*
Aniline Compounds / diagnostic use
Brain Mapping
Cognition Disorders* / classification,  pathology,  radionuclide imaging
Female
Follow-Up Studies
Hippocampus / pathology,  radionuclide imaging
Humans
Magnetic Resonance Imaging / methods*
Male
Middle Aged
Neuropsychological Tests
Positron-Emission Tomography / methods*
Psychometrics / methods
Thiazoles / diagnostic use
Grant Support
ID/Acronym/Agency:
K02 AG 001039/AG/NIA NIH HHS; K02 AG 027998/AG/NIA NIH HHS; K23 AG 028018/AG/NIA NIH HHS; K23 AG028018/AG/NIA NIH HHS; K23 AG028018-04/AG/NIA NIH HHS; P01 AG 025204/AG/NIA NIH HHS; P01 AG025204/AG/NIA NIH HHS; P01 AG025204-04/AG/NIA NIH HHS; P01 AG025204-04S1/AG/NIA NIH HHS; P01 AG025204-05/AG/NIA NIH HHS; P01 AG025204-06/AG/NIA NIH HHS; P01 AG025204-07/AG/NIA NIH HHS; P01 AG025204-08/AG/NIA NIH HHS; P50 AG 005133/AG/NIA NIH HHS; P50 AG005133/AG/NIA NIH HHS; P50 AG005133-25/AG/NIA NIH HHS; R01 AG 018402/AG/NIA NIH HHS; R01 AG 020098/AG/NIA NIH HHS; R01 AG 020226/AG/NIA NIH HHS; R01 AG020098/AG/NIA NIH HHS; R01 AG020098-05/AG/NIA NIH HHS; R01 MH 070729/MH/NIMH NIH HHS; R37 AG 025516/AG/NIA NIH HHS; R37 AG025516/AG/NIA NIH HHS; R37 AG025516-01/AG/NIA NIH HHS; R37 AG025516-02/AG/NIA NIH HHS; R37 AG025516-03/AG/NIA NIH HHS; R37 AG025516-04/AG/NIA NIH HHS; R37 AG025516-05/AG/NIA NIH HHS; R37 AG025516-05S1/AG/NIA NIH HHS; R37 AG025516-06/AG/NIA NIH HHS; R37 AG025516-07/AG/NIA NIH HHS; R37 AG025516-08/AG/NIA NIH HHS
Chemical
Reg. No./Substance:
0/2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole; 0/Amyloid; 0/Aniline Compounds; 0/Thiazoles
Comments/Corrections
Erratum In:
Ann Neurol. 2009 Jul;66(1):123
Note: DeKoskym, Steven T [corrected to De-Kosky, Steven T]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Glutathione peroxidase activity modulates recovery in the injured immature brain.
Next Document:  Remission of epilepsy after two drug failures in children: a prospective study.